Research

Personalizing Immunotherapy
Early Stage Lung Cancer microbiome and blood-based markers

Benefit to Patients
Using biomarkers for personalizing immunotherapy in early stage lung cancer to determine which patients will likely benefit or experience toxicities from our new immunotherapy studies.

Boris Sepesi, M.D.
The University of Texas MD Anderson Cancer Center
Thank You Letter

Personalizing Immunotherapy
In metastatic lung cancer, including autantibodies & genomic markers

Benefit to Patients
Improving patient selection of who will likely benefit or experience toxicities from our new immunotherapy studies.

Mehmet Altan, M.D. &
Boris Sepesi, M.D.
The University of Texas MD Anderson Cancer Center
Thank You Letter

Targeted Treatment
To correlate the microorganisms in the gut with the risk of inflammation of the colon and response to immunotherapy.

Benefit to Patients
To better understand the impact of modifying the gut microbiome to impact response rates to immunotherapy and protect patients from colon inflammation.

Mehmet Altan, M.D.
The University of Texas MD Anderson Cancer Center
Thank You Letter

Targeted Treatment
To determine the biomarkers for selecting which patients benefit from aggressive local consolidative therapy.

Benefit to Patients
Traditionally Oligometastic lung cancer has only spread to limited number of sites, and has been treated only with chemo. This study will seek to determine benefits from surgery and radiation in addition to systemic therapy.

Daniel Gomez, M.D. &
Jianjun Zhang, M.D., Ph.D.
The University of Texas MD Anderson Cancer Center
Thank You Letter

Targeted Treatment
To understand how EGFR/HER2 exon 20 mutant non-small cell lung cancer develops resistance to poziotinib.

Benefit to Patients
To provide patients who have tumors that have become resistant to treatments, a new combination of drugs to overcome that resistance.

Jacqulyne Robichaux, Ph.D.
The University of Texas MD Anderson Cancer Center
Thank You Letter